# Legend Capital

> Legend Capital is a VC fund in Beijing backing Health Care and Medical. See 432 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Beijing, China
- Total investments: 432
- Last investment: Jul 2026
- Lead investor: 39%
- Fund size: $177M
- Last fund: Nov 2021
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/legend-capital
- Website: http://www.legendcapital.com.cn

Legend Capital is a VC fund in Beijing focused on Health Care and Medical. Legend Capital, a subsidiary of Legend Holdings Ltd., started its vintage year in April, 2001 with a mission to become a top-notch and the most respected venture capital investment manager in China.Managing up to US$700 million across four funds, Legend Capital focuses on driving high-growth ventures with operations substantially based in Chinaor on markets related to China.Legend Capital mainly invests in early stage IT companies, specifically, in sectors of network applications and services, outsourcing and professional services, Infrastructure (IC design/key components), and mid-market growth stage companies in the fields of consumer goods, clean technology, health care, equipment manufacturing and modern services.Among over 60 portfolio companies are Joyo.com (acquired by Amazon.com), SinoCom (0299.HK), Solarfun Power (Nasdaq: SOLF), Spreadtrum Communications (Nasdaq: SPRD), China Sunshine Paper (2002.HK), and VanceInfo (NYSE:VIT), Eyang (0117.HK), etc.As an active investor, Legend Capital provides its portfolio companies extensive business resources and tailored services to assist with business development, company image building, and other critical company building activities on Chinese market so as to add value and maximize returns. Legend Capital is proud and thankful that it has the opportunity to blaze a trail with its innovative practice for China's venture capital industry.

## Contacts

5 contacts available for Legend Capital. Shizune tracks 18 team members at Legend Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/legend-capital?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $2.9M–$100M |
| Series B | $12M–$115M |
| Series C | $15M–$200M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 63 | 15% |
| Medical | 51 | 12% |
| Biotechnology | 45 | 10% |
| Manufacturing | 32 | 7% |
| Artificial Intelligence | 29 | 7% |

194 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 106 | 25% |
| Series A | 73 | 17% |
| Series C | 64 | 15% |
| Series D | 22 | 5% |
| Seed | 19 | 4% |

11 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 223 | 52% |
| United States | 19 | 4% |
| South Korea | 4 | 1% |
| Japan | 2 | 0% |
| Singapore | 2 | 0% |

9 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Hongbin Zhou | Managing Director | 4 | https://shizune.co/investors/profile/zhou-hongbin |
| Jianqing Wang | Managing Director and Chief Management Advisor | 1 | https://shizune.co/investors/profile/wang-jianqing |
| Joon Park | Co-CIO | 8 | https://shizune.co/investors/profile/joon-sung-park |
| Tony WANG | VP | 3 | https://shizune.co/investors/profile/tony-wang-6 |
| Yi Kang | Director | 1 | https://shizune.co/investors/profile/yi-kang |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Beyond Therapeutics | Beyond Therapeutics employs its ExCEED technology to speed the discovery and development of novel medications for unmet therapeutic needs. | $29.6M | Series A | Jul 30, 2026 |  |
| Liangyi Wanxiang | Liangyi Wanxiang is focuses on complete machines, product R&D, and technological innovation in atomic quantum computing. |  | Series A | Jul 19, 2026 |  |
| Mochi Intelligence | Mochi Intelligence is a high-tech enterprise specializing in the research and development of embodied intelligent robots. The company is committed to creating intelligent robots including humanoid robots that can truly understand and adapt to the real world through cutting-edge artificial intelligence technology and robotics. | $147.2M | Seed | Jul 06, 2026 |  |
| Qiuzhi Technology | Qiuzhi Technology focused on merging artificial intelligence and robotics, with an objective of bringing robots into households. | $100M | Angel | Jul 01, 2026 |  |
| Lingtai Krypton Biotechnology | Lingtai Krypton Biotechnology is an innovative corporation that specializes in the development of lncRNA drugs. |  | Series A | Jun 26, 2026 |  |
| Noitom Robotics | Noitom Robotics is an intelligent robot development company specializing in the sales, installation, and maintenance of industrial robots, as well as the sale of consumer robots and the research and development of intelligent robots. |  | Seed | Jun 16, 2026 |  |
| Huayi Quantum | Huayi Quantum is a quantum computer and quantum cloud platform developer specializing in advanced algorithm research and application acceleration.The business creates modular, standardized, and scalable quantum computers based on ion-trap technology. |  | Series A | Jun 09, 2026 |  |
| Optical Interconnect Technology | Optical Interconnect Technology is a pioneer in the domestic optical interconnect market, specializing in inter-chip optical interconnects for high-performance computing applications. | $73.9M | Series A | Jun 03, 2026 |  |
| Shunyuan Technology | Shunyuan Technology is a high-tech enterprise specializing in the development of fusion simulators and advanced route design solutions, providing innovative technologies and intelligent systems for complex engineering, transportation, and industrial applications. |  | Seed | Jun 03, 2026 |  |
| Zhenyu Bio | Zhenyu Bio is a biopharmaceutical service provider that specializes in the development of next-generation universal cell therapy products, such as in vivo CAR-T and innovative universal therapeutic cell vaccines. | $14.7M | Series A | May 27, 2026 |  |

10 of 432 investments shown.

## Co-investors
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund, 40 deals together
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund, 25 deals together
- [Tencent](https://shizune.co/investors/profile/tencent) — VC Fund, 18 deals together
- [Matrix Partners China](https://shizune.co/investors/profile/matrix-partners-china) — VC Fund, 17 deals together
- [Lenovo Capital and Incubator Group (LCIG)](https://shizune.co/investors/profile/lenovo-capital-and-incubator-group-lcig) — VC Fund, 13 deals together
- [Gaorong Capital](https://shizune.co/investors/profile/banyan-capital) — VC Fund, 12 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [HSG](https://shizune.co/investors/profile/sequoia-capital-china) — VC Fund

## Featured in investor lists
- [All Investors in Asia](https://shizune.co/investors/investors-asia)
- [All VC Funds in Asia](https://shizune.co/investors/vc-funds-asia)
- [All Investors in China](https://shizune.co/investors/investors-china)
- [All VC Funds in China](https://shizune.co/investors/vc-funds-china)
- [SaaS Investors in Asia](https://shizune.co/investors/saas-investors-asia)
- [SaaS VC Funds in Asia](https://shizune.co/investors/saas-vc-funds-asia)

## FAQ

### What does Legend Capital invest in?

Legend Capital invests primarily in Health Care, Medical and Biotechnology startups, most often at Series B and Series A stage. Most of the 432 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Legend Capital's check size?

Legend Capital typically joins rounds of $2.9M–$100M at Series A, $12M–$115M at Series B and $15M–$200M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Legend Capital participates in.

### How do I contact Legend Capital?

Public channels for Legend Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Legend Capital?

The team at Legend Capital includes Hongbin Zhou (Managing Director), Jianqing Wang (Managing Director and Chief Management Advisor) and Joon Park (Co-CIO), among 18 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co